"Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”

To order this detailed 485+ page report, please visit this – https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

Key Inclusions

A detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration. In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.

Detailed profiles of large players that are engaged in the development of synthetic lethality-based drugs (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and an excerpt on its developmental history. In addition, the chapter includes tabulated profiles of small-sized and mid-sized players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as location of headquarters, year of establishment, number of employees, and key members of the executive team), recent developments, along with descriptions of their synthetic lethality-based drug candidates.

An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.

An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment. It includes an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, synlet targets, and analysis based on various relevant parameters, such as study type (review article, research article and case report), research objective, year of publication, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor).

An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts). In addition, this analysis features a multi-dimensional bubble chart analysis to assess the relative level of expertise of the key authors / researchers based on the number of publications, citation count and research gate score.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Type of Molecule

Small Molecule

Biologic

Target Indication

Breast Cancer

Cervical / Anogenital Cancer

Diabetic Macular Edema

Gastric Cancer

Lung Cancer

Ovarian Cancer

Renal Cell Cancer

Synlet Target

APE / REF-1

CHK1

GLS1

PARP

Polθ

WEE1

Route of Administration

Oral

Intravenous

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

The report includes detailed transcripts of discussions held with the following experts:

Simon Boulton (Vice President, Science Strategy, Artios Pharma)
Yi Xu (Associate Director, Business Development, IMPACT Therapeutics)
Norbert Perrimon (Professor, Department of Genetics, Harvard Medical School)
Vivek Dharwal (Professor, Department of Biochemistry, Panjab University)
Alfred Nijkerk (Chief Executive Officer, UbiQ)

To request sample pages, please visit this link

Key Questions Answered

What are the prevalent R&D trends related to synthetic lethality?
What type of clinical conditions can be treated using synthetic lethality-based drugs?
What are the key drug classes that leverage the concept of synthetic lethality?
Who are the leading industry and non-industry players in this market?
What are the most popular synlet targets and target indications?
What are the key geographies where research on synthetic lethality is being conducted?
Who are the key investors in this domain?
Who are the key opinion leaders / experts in this field?
How is the current and future market opportunity likely to be distributed across key market segments?

You may also be interested in the following titles: